Iovance Biotherapeutics

$35.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.79 (-2.15%) As of 10:34 AM EDT today

Why Robinhood?

You can buy or sell IOVA and other stocks, options, and ETFs commission-free!

About IOVA

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Read More Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. The listed name for IOVA is Iovance Biotherapeutics, Inc. Common Stock.

Employees
148
Headquarters
San Carlos, California
Founded
2007
Market Cap
5.14B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.77M
High Today
$36.18
Low Today
$34.01
Open Price
$34.03
Volume
252.97K
52 Week High
$41.49
52 Week Low
$18.70

Collections

IOVA Earnings

-$0.55
-$0.37
-$0.18
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
-$0.46 per share
Actual
Expected Nov 2, After Hours

You May Also Like